Holen Sie sich die Stockscreener-App
117.39
1.50%
1.74
Schlusskurs vom Vortag:
$115.65
Offen:
$115.36
24-Stunden-Volumen:
1.91M
Relative Volume:
1.12
Marktkapitalisierung:
$23.45B
Einnahmen:
$5.36B
Nettoeinkommen (Verlust:
$1.43B
KGV:
16.60
EPS:
7.0718
Netto-Cashflow:
$1.42B
1W Leistung:
+2.18%
1M Leistung:
+19.52%
6M Leistung:
+12.15%
1J Leistung:
+74.22%
1-Tages-Spanne:
$114.80
$118.95
1-Wochen-Bereich:
$110.56
$119.60
52-Wochen-Spanne:
$67.20
$119.60
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
117.39 | 23.10B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
482.00 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
675.19 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
874.74 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.29 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.37 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Benchmark reiterates Halozyme stock Buy rating on Incyte deal - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Halozyme deal - Investing.com
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Corp (INCY) grants RSUs and stock options to accounting chief - Stock Titan
Incyte Corp (INCY) CMO awarded RSUs, options and sells stock - Stock Titan
Incyte Corp (INCY) awards RSUs, options and performance shares to CSO - Stock Titan
Equity grants to INCYTE CORP (INCY) R&D head and holdings - Stock Titan
Incyte (INCY) grants RSUs, options and performance shares to EVP - Stock Titan
Incyte Corp (INCY) awards RSUs, options and performance shares to EVP - Stock Titan
Incyte (NASDAQ: INCY) awards RSUs, options and performance shares to EVP - Stock Titan
INCYTE CORP (INCY) grants CEO stock options, RSUs and performance shares - Stock Titan
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme and Incyte announce global collaboration deal - grafa.com
Incyte adds Halozyme’s ENHANZE tech to first-in-class myeloproliferative neoplasm therapy - AllSci
Halozyme partners with Incyte on drug delivery technology - Investing.com
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - The AI Journal
Halozyme-Incyte Deal Aims for More Convenient INCA033989 Dosing - Stock Titan
Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation - ChartMill
INCY: Incyte Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers - The AI Journal
Incyte to present Phase 1 cancer data at ESMO Congress - Investing.com
Incyte stock hits 52-week high at 118.98 USD - Investing.com
Incyte CMO Steven Stein sells $3.19m in company stock By Investing.com - Investing.com South Africa
Incyte CMO Steven Stein sells $3.19m in company stock - Investing.com UK
Form 4 Incyte Corporation For: 16 July By Investing.com - Investing.com Nigeria
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Lobbying Update: $110,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Incyte (INCY) R&D chief withholds 22,919 shares to cover taxes - Stock Titan
Incyte Corp (NASDAQ: INCY) EVP reports 1,949-share RSU tax withholding - Stock Titan
Incyte Corp (NASDAQ: INCY) PAO reports 1,790 shares withheld for RSU taxes - Stock Titan
What to Expect From Incyte's Q2 2026 Earnings Report - Barchart.com
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
INCY Maintains Overweight Rating -- Price Target Raised to $134 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on VWD drug data - Investing.com
H.C. Wainwright reiterates Incyte stock rating on VWD drug data By Investing.com - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (INCY) Reveals Promising Data for New Treatment in Von Wi - GuruFocus
Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3 - Yahoo Finance
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types - BioBuzz
How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis - Yahoo Finance
BMO raises Incyte stock price target to $112 on Opzelura strength - Investing.com Nigeria
INCY Maintained by BMO Capital -- Price Target Raised to $112 - GuruFocus
BMO raises Incyte stock price target to $112 on Opzelura strength By Investing.com - Investing.com South Africa
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disord - Benzinga
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks - Yahoo Finance
Incyte reports 81% bleeding reduction in VWD study - grafa.com
Incyte reports phase 1/2 trial results for bleeding disorder drug By Investing.com - Investing.com South Africa
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.50%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):